Tuesday, March 30, 2010 8:53:13 AM
Caraco Pharmaceutical gets FDA approval for generic version of cancer drug Eloxatin
Companies:Caraco Pharmaceutical Laboratories Ltd.Banco Santander-ChileTeva Pharmaceutical Industries Limited
On Thursday March 11, 2010, 2:54 pm EST
DETROIT (AP) -- Caraco Pharmaceutical Laboratories Ltd. said Thursday it launched a generic version of Sanofi-Aventis' cancer treatment Eloxatin.
Teva Pharmaceutical Industries Ltd. also sells a generic version of the drug, which is aimed at colon and rectal cancer.
Caraco said it is launching the 50 milligram and 100 milligram generic doses of the drug after the FDA approved Sun Pharma's application. Caraco is a subsidiary of Sun Pharma.
The company said Oxaliplatin injections, the generic name for Eloxatin, have annual sales of about $1.3 billion in the U.S.
Shares of Caraco rose 37 cents, or 7.8 percent, to $5.12 in afternoon trading. The stock has traded between $1.75 and $6.79 over the last 52 weeks.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM